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Crosspresentation is a specialized function of
myeloid dendritic cells (mDCs), allowing them
to induce CD8+ T cell responses against exoge-
nous antigens that are not directly produced
in their cytotosol. Human plasmacytoid DCs
(pDCs) are not considered so far as able to per-
form crosspresentation. We showed here that
purified human pDCs crosspresented vaccinal
lipopeptides and HIV-1 antigens from apoptotic
cells to specific CD8+ T lymphocytes. Apoptotic
debris were internalized by phagocytosis and
the lipopeptide LPPol reached nonacidic endo-
somes. This crosspresentation was amplified
upon influenza virus infection. Importantly, the
efficiency of crosspresentation by pDCs was
comparable to that of mDCs. This property of
human pDCs needs to be taken into account
to understand the pathogenesis of infectious,
allergic, or autimmune diseases and to help
achieve desired responses during vaccination
by targeting specifically either type of DCs.
INTRODUCTION
Plasmacytoid dendritic cells (pDCs) are a subset of DCs
present in the blood and in lymphoid organs (Cella et al.,
2000; Grouard et al., 1997). Their main function is the pro-
duction of type I interferons (IFN) in response to microbial
stimuli (Cella et al., 2000; Ito et al., 2006; Kadowaki et al.,
2000; Siegal et al., 1999). pDCs die rapidly by apoptosis
unless rescued by IL-3, type I IFN, or factors inducing
type I IFN secretion (Grouard et al., 1997). They expressImCD4 and major histocompatibility complex (MHC) class
II molecules but lack molecules specific for the T, B, NK,
or monocytic lineages. pDCs also express BDCA-2, a spe-
cific membrane lectin (Dzionek et al., 2001), CD123, the
a chain of the IL-3 receptor, and neuropilin-1 (BDCA-4).
DCs are the only antigen-presenting cells (APCs) that
stimulate naive T lymphocytes (Banchereau and Stein-
man, 1998). CD8+ T lymphocytes are essential in immune
responses to viruses and tumors. They recognize peptide-
class I MHC complexes. These complexes are generated
either after direct presentation, as a result of endogenous
production of the antigens in the cytosol, or after cross-
presentation, which occurs after internalization of exoge-
nous antigens into endocytic compartments, followed in
most of the cases by export into the cytosol. This allows
presentation of antigens from microorganisms that do
not infect DCs, from tumor cells, and from autologous
cells (Bevan, 1976). In the cytosol, antigens are generally
digested by the proteasome (Seifert et al., 2003), further
trimmed by other enzymes, transported into the endoplas-
mic reticulum, and then associated with the heavy chain of
MHC class I molecules and with b2-microglobulin, allow-
ing export to the cell surface and presentation to CD8+ T
lymphocytes (Cresswell et al., 2005; Rock and Shen,
2005). Crosspresentation may be the predominant anti-
gen-presentation pathway for many infections, depending
on the availability of DCs at the site of infection and on
their infectability (Chen et al., 2004; Heath et al., 2004;
Rock and Shen, 2005). Particularly, viral proteins from
apoptotic, infected cells can be crosspresented by DCs
(Albert, 2004).
T cell responses to antigen presentation depend on
three signals. Signal 1 is the antigen-specific signal medi-
ated by the MHC-peptide complex. Signal 2 is mediated
by interactions of CD40, CD80, CD86, and other costimu-
latory molecules with their T cell ligands. Signal 3 is the po-
larizing signal, mediated by soluble or membrane-boundmunity 27, 481–492, September 2007 ª2007 Elsevier Inc. 481
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Crosspresentation by Human Plasmacytoid DCfactors, such as interleukin-12 (IL-12), type I IFN, or IL-10.
Signal 3 promotes the development of either T helper type
1 (Th1), T helper type 2 (Th2), or regulatory T (Treg) cell
responses (Kapsenberg, 2003). Sensitization of naive T
lymphocytes by DCs results in immunity or tolerance, de-
pending on modulation of the three signals by the environ-
ment and on the nature of the DCs (Albert et al., 2001;
Moser, 2003; O’Garra and Vieira, 2004; Reis e Sousa,
2006; Shortman and Heath, 2001; Sporri and Reis e
Sousa, 2005; Steinman et al., 2003). Toll-like receptor
(TLR) ligands like imiquimod (R-837) and CpG oligonucle-
otides are recognized by TLR 7 and 9, respectively, on
pDCs, whereas bacterial wall-derived LPS is recognized
by TLR 4 on mDCs. Binding of these ligands induces mat-
uration of the respective DCs, including enhancement of
the three signals governing T cell stimulation. Combination
of intracellular and extracellular TLR signaling leads to
synergic responses (Napolitani et al., 2005; Trinchieri
and Sher, 2007).
Antigen presentation by DCs has mostly been studied
in human monocyte-derived DCs and in murine bone-
marrow-derived or spleen DCs (Guermonprez et al.,
2002). pDCs were first considered to have a minor role in
antigen uptake and presentation (Grouard et al., 1997).
Nevertheless, human blood pDCs internalize Lucifer
yellow (Dzionek et al., 2001) and antibody-bound MHC
class II-restricted antigens (Benitez-Ribas et al., 2006;
Dzionek et al., 2001; Zhang et al., 2006), and mouse spleen
pDCs phagocytose latex beads (Ochando et al., 2006).
The role of pDCs in T cell polarization has been mainly
studied in mixed lymphocyte reactions. After stimulation
by influenza A virus (IAV) or by CD40 ligand (CD40L),
pDCs are as efficient as mDCs to induce strong type 1 T
helper cell proliferation and high production of IFN-g (Cella
et al., 2000). After stimulation with IL-3 or herpes simplex
virus (HSV)-1, they induce naive CD4+ T cells to produce
IL-4 or IL-10, respectively (Kadowaki et al., 2000). In addi-
tion, human pDCs can induce Treg cells in vitro (Gilliet and
Liu, 2002; Kawamura et al., 2006; Moseman et al., 2004).
Human pDCs present peptides in association with MHC
class I antigen molecules as effectively as mDCs (Fon-
teneau et al., 2003; Lore et al., 2003; Salio et al., 2003).
After exposure to IAV in vitro, pDCs efficiently activate
influenza-specific Th1 CD4+ and CD8+ CTL memory re-
sponses (Fonteneau et al., 2003). In vivo, murine pDCs
loaded with a lymphocytic choriomeningitis virus peptide
induce primary CD8+ T cell responses when they are pre-
activated by IAV (Schlecht et al., 2004). Therefore, pDCs
perform most of the functions that are necessary for
crosspresentation, i.e., endocytosis, processing, and pre-
sentation of viral antigens, and mature pDCs display full
T cell stimulation capacity. However, murine pDCs were
claimed to be unable to induce crosspriming in vivo (Salio
et al., 2004). In addition, in contrast to mDCs, human pDCs
do not crosspresent the full-length tumor protein NY-
ESO-1 in vitro, even when stimulated by TLR ligands or
by CD40L (Schnurr et al., 2005). Therefore, it is important
to assess whether pDCs perform crosspresentation in
a physiological manner.482 Immunity 27, 481–492, September 2007 ª2007 Elsevier IncWe tested crosspresentation of a candidate HIV lipo-
peptide vaccine that is endocytosed and crosspresented
by monocyte-derived DCs to CD8+ T lymphocytes spe-
cific for HIV-1 epitopes (Andrieu et al., 2003). We also
used, as a source of antigens, apoptotic cells expressing
HIV proteins. Here we demonstrate that human blood
pDCs were able to perform crosspresentation.
RESULTS
Purified Human pDCs Crosspresent Vaccinal
Antigens to Specific T Lymphocytes
Lipopeptides containing peptides from several proteins
from the Lai sequence of HIV-1 (HIV-1Lai), coupled to the
tetanus toxoid TT830-843 helper peptide, are currently
used in clinical trials in volunteers and HIV-infected
patients (Durier et al., 2006). Lipopeptides are crosspre-
sented by monocyte-derived DCs and induce CD4+ and
CD8+ T cell responses (Andrieu et al., 2003; Gahery
et al., 2005). To test crosspresentation by pDCs, BDCA-
4+ cells were selected positively after depletion of other
cells from peripheral blood mononuclear cells (PBMCs)
obtained from healthy donors (Figure 1A). Purified pDCs
were incubated with a vaccinal lipopeptide preparation,
and IAV was added to induce pDC maturation. Plasmacy-
toid DCs were then washed and cultured with a Gag77-85-
specific primary T cell line. An efficient antigen-specific
T cell stimulation by pDCs was evidenced by IFN-g
ELISPOT (Figure 1B). Similar results were obtained with
two single lipopeptides including either the HIV-1Lai
Nef66-97 (LPNef) or Pol461-484 sequence (LPPol) (Andrieu
et al., 2003) and specific T cell lines (Figure 1B). MHC class
I restriction was assessed by immunomagnetic depletion
of the CD8+ (81%) or the CD4+ (14%) T cells contained
in the Pol476-484-specific T cell line: IFN-g responses
required CD8+ and not CD4+ T cells (Figure 1C). These
data show that pDCs crosspresent different vaccinal lipo-
peptides to CD8+ T cells specific for different epitopes and
restricted by different MHC class I antigens.
Plasmacytoid DCs were then compared to conventional
mDCs for crosspresentation of the LPPol lipopeptide.
Purified pDCs or mDCs were incubated for 12 hr with
LPPol, then washed and cultured with a Pol476-484-specific
T cell line. Plasmacytoid DCs and mDCs induced similar
IFN-g responses to the lipopeptide (Figure 2A). Lipopep-
tide and epitopic peptide presentation were increased
by incubating mDCs with LPS or pDCs with IAV; con-
versely, LPS did not enhance presentation by pDCs,
which lack TLR 4, and IAV did not enhance presentation
by mDCs (Figure 2A), perhaps because it was cytotoxic
for those cells, as noted before (Cella et al., 2000; Fonte-
neau et al., 2003). Purified pDC populations may contain
a few contaminating mDCs. To test whether small num-
bers of mDCs would stimulate T cell responses as effi-
ciently as the whole pDC population, experiments were
performed with decreasing numbers of pDCs or mDCs.
T cell responses decreased proportionally to the number
of mDCs and were undetectable at numbers higher than
those potentially corresponding to the few contaminating.
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Crosspresentation by Human Plasmacytoid DCFigure 1. Plasmacytoid DCs Crosspresent Antigens from Vaccinal Lipopeptides
(A) pDCs were purified with BDCA4 antibody-coated magnetic beads from PBMCs after depletion of non-pDC cells. Purity was assessed by FACS by
forward and side scatter characteristics (FSC and SSC), expression of HLA-DR but not of different cell lineage (Lin)-specific molecules, and expres-
sion of the IL3 receptor a chain (CD123) and of BDCA2, a pDC-specific lectin.
(B) Left: pDCs were loaded with the vaccinal lipopeptide preparation LPHIV1, then cultured in the presence of influenza A virus; they were used as
APCs to stimulate HIV-1 Gag77-85-specific, HLA-A2-restricted, primary CD8
+ T cells in an IFN-g ELISPOT assay. Middle: lipopeptide LPNef-loaded
pDCs, cultured in the presence of CpG, were used to stimulate Nef73-82-specific, HLA-A3-restricted T cells. Right: lipopeptide LPPol-loaded pDCs,
cultured in the presence of R-837, were used to stimulate Pol476-484-specific, HLA-A2-restricted T cells. Tax, HTLV-1 HLA-A2-restricted peptide.
(C) CD8+ T cell dependence of the response. pDCs were incubated with either control peptides or LPPol, then with the unseparated Pol476-484-specific
T cell line, or with different cell fractions. Alternatively, the T cell line was incubated with LPPol and no DCs. Data are represented as mean ± SEM
(n = 3 replicates) and representative of at least two independent experiments.mDCs in pDC populations (Figure 2B). This was also true
when responses were stimulated by LPS (that increased
responses induced by mDCs) or IAV (that increased re-
sponses induced by pDCs) (Figure 2B). B lymphocytes,
which are also APCs, do not account for the presentation
activity found in the pDC population (Figure S1 in the Sup-
plemental Data available online). If small numbers of
mDCs by themselves cannot account for antigen presen-
tation, they might have been stimulated when mixed with
pDCs. Indeed, in mixed populations, it was reported that
HIV induces IFN-a secretion by pDCs, which in turn induce
bystander mDC maturation (Fonteneau et al., 2004). How-
ever, adding 10% or 20% of contaminating mDCs to puri-
fied pDCs did not change T cell responses, showing that
mDCs did not synergize with pDCs for crosspresentation
(Figure 2C). Therefore, pDCs crosspresent the Pol476-484
epitope from the lipopeptide to specific T lymphocytes,
and this presentation is not attributable to contaminating
APCs.
Lipopeptide Uptake and Crosspresentation
by pDCs
We then assessed by flow cytometry and confocal
microscopy how pDCs take up the Pol lipopeptide. The
Rhodamine-labeled lipopeptide analog (LPPol-Rho) (An-
drieu et al., 2003) was first incubated with fresh PBMCs
(Figure S2). Even as a minor population of 0.83% amongImPBMCs, pDCs efficiently captured the lipopeptide like
mDCs. Purified pDCs also internalized the lipopeptide
rapidly, through an active, temperature-dependent mech-
anism (Figure 3A). After 1 hr, pDCs were homogenously
labeled in intracellular compartments reminiscent of en-
dosomal structures. To assess whether the lipopeptide
was internalized through endocytosis, purified pDCs
were first surface-labeled with BDCA-2 mAbs at 4C,
then washed and incubated with lipopeptide at 37C, al-
lowing simultaneous endocytosis of BDCA-2 bound anti-
bodies and of the lipopeptide. After 30 min, the lipopep-
tide colocalized with BDCA-2-labeled endosomes in
most of the pDCs (Figure 3B). Single channel intensity
false-color labeling revealed a clear localization of
BDCA-2 in endosomes, whereas the lipopeptide ap-
peared in addition in a larger, fuzzy zone around endo-
somes (Figure 3B, middle). Recent reports suggest that
efficient MHC class II-restricted antigen presentation
correlates with the induction of signaling events from
endosomes containing both the antigen and a TLR ligand
(Blander and Medzhitov, 2006). We investigated whether
the lipopeptide used the same compartment as the TLR-
9 ligand CpG B-FITC, complexed to DOTAP so as to
gain access to early endosomes like CpG A (Guiducci
et al., 2006; Honda et al., 2005). The lipopeptide was found
underneath the surface of BDCA-2-labeled extensions
and colocalized with CpG B-DOTAP in intracellularmunity 27, 481–492, September 2007 ª2007 Elsevier Inc. 483
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Crosspresentation by Human Plasmacytoid DCFigure 2. Crosspresentation by pDCs, Not Contaminating mDCs
(A) Crosspresentation by purified pDCs or mDCs. Plasmacytoid DCs and mDCs were loaded with LPPol, the negative control LPNef, or the positive
epitope control Pol476-484, and left unstimulated (NS) or stimulated with either IAV or LPS; they were then incubated with a CD8
+ T cell line specific for
Pol476-484. Results are shown here for 15,000 DCs and 45,000 T cells/well, as the number of IFN-g ELISPOTS/well.
(B) Small numbers of mDCs do not achieve crosspresentation. Left, control responses to Pol476-484- or LPNef-loaded DCs; right, CD8
+ T cells
response to decreasing numbers of LPPol-loaded DCs unstimulated (top) or stimulated with IAV (middle) or LPS (bottom).
(C) No synergistic effect between pDCs and mDCs for antigen crosspresentation. Left: control responses to purified pDCs or mDCs as in (B). Right:
different proportions of mDCs were added to pDCs before loading with LPPol. The final number of APCs is equal to 10,000/well in the IFN-g ELISPOT
assay. Data are represented as mean ± SEM (n = 3 replicates) and representative of at least two independent experiments.vesicles (Figure 3C). We then assessed whether the lipo-
peptide reached acidic, late endosomes or lysosomes,
labeled by LysoTracker (Trombetta et al., 2003). Vesicles
containing LPPol (Figure 3D, left) were often in close con-
tact with LysoTracker-positive vesicles, without clear-cut
colocalization (Figure 3D, middle). If a minor part of the lip-
opeptide colocalized with LysoTracker, this was in a small
proportion of cells and after at least 60 min of incubation
(Figure 3D, right). The mean intensity of lipopeptide label-
ing in the LysoTracker-positive vesicles was lower than in
the others. This suggests either that the lipopeptide is de-
graded in these acidic vesicles or that it moves toward the
cytosol before or when it reaches them. These results
show that the Pol lipopeptide is internalized into endoso-
mal vesicles where it colocalizes with CpG B-DOTAP,
mostly in nonacidic endosomes.
Presentation of LPPol was dependent on intracellular
processing by the proteasome, as assessed by dose-de-
pendent inhibition by lactacystin or epoxomycin, which
had no or limited toxic inhibitory activity on presentation
of the Pol epitope added exogenously (Figures 3E and
3F). Together with the data showing internalization into
endosomal compartments, these data confirm the cross-
presentation of the lipopeptide.484 Immunity 27, 481–492, September 2007 ª2007 Elsevier IncPurified Human pDCs Internalize
and Crosspresent Antigens from Apoptotic Cells
Expressing HIV Proteins
Epitopes from apoptotic, infected cells are a major source
of antigens for crosspresentation (Albert, 2004; Chen
et al., 2004; Heath et al., 2004). HIV-1 antigens originating
from apoptotic, infected CD4+ T cells are very efficiently
crosspresented by monocyte-derived DCs and mDCs
(Maran˜o´n et al., 2004). We assessed whether pDCs would
also crosspresent antigens from apoptotic, infected cells.
Purified pDCs were cultured with PKH-labeled, apoptotic
H9 cells that were chronically infected with HIV. Flow cy-
tometry showed that PKH67 was associated with pDCs
in a temperature-dependent manner. This association
was mostly dependent on actin polymerization, as indi-
cated by the fact that it was inhibited by 80% by latruncu-
lin B and by 60% by cytochalasin D (Figure 4A). Further
demonstration of real internalization by phagocytosis
was brought by confocal microscopy showing apoptotic
fragments in endosome-like structures (Figures 4B and
4C). To assess functional crosspresentation, purified
pDCs were cultured with apoptotic H9HIV cells in the
presence of 30-azido-30-deoxythymidine (AZT) to inhibit
viral replication, then washed and used as APCs..
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Crosspresentation by Human Plasmacytoid DCStimulation of T cell lines specific for different HIV epi-
topes was evidenced by IFN-g ELISPOT (Figure 4D).
pDCs also crosspresented HIV antigens from apoptotic,
infected PBMCs (PHA blasts) to a Gag77-85-specific T
cell line (Figure 4E, bottom right). Moreover, PBMCs
from an HIV-infected patient underwent strong HIV-spe-
cific proliferation after culture with apoptotic, infected
PHA blast-loaded pDCs, and not with uninfected PHA
blast-loaded pDCs or with infected PHA blasts alone
(Figure 4E). Because the antigen donor cells were infected
with HIV, pDCs might have been productively infected by
HIV and have presented directly antigens derived from en-
dogenous viral proteins. To avoid viral replication, experi-
ments were performed in the presence of antiretroviral
drugs (azidothymidine [AZT], a nucleosidic reverse tran-
scriptase inhibitor, or AMD3100[AMD], a fusion inhibitor
analog to CXCR4), or H9HIV cells were treated by saqui-
navir (SQ), a HIV protease inhibitor. Addition of these
drugs at concentrations that inhibited HIV-1Lai replication
(data not shown) did not decrease T cell stimulation by
pDCs incubated with apoptotic H9HIV cells (Figure 5A).
Virus production was not detected upon exposure of
pDCs with cell-free virus, added at amounts similar to
those contained in H9HIV cells or in PHA blasts (Figure S3).
Gag-specific IFN-g responses were not elicited either, and
300 to 1000 times more virus was necessary to induce
a relatively low response (Figure 5B).
In addition, we showed crosspresentation with three
different HIV-1Lai antigen-donor cells that do not produce
viral particles: Jurkat cells transduced with a lentiviral vec-
tor vector coding for Nef, CEM clones stably express-
ing Nef, or fibroblasts transiently transfected with a gag
gene. When these cells were irradiated to induce apopto-
sis and cocultured with pDCs, the pDCs activated the rel-
evant CTLs (Figure 5C). There was a possibility that the
donor cells rather than the DCs were directly presenting
the antigen. However, the donor cells did not express
the HLA molecule that restricted the response of the cell
lines, except for the nef-transduced Jurkat cells (HLA-
A3, which binds HIV-1Lai Nef73-82; Table S1). Presentation
and stimulation by the antigen donor cells was ruled out
in all the cases, by testing these cells alone without DCs
(Figures 4D, 4E, 5C, and 6A). These data show that T
cell responses were due to crosspresentation and not to
direct viral presentation.
Plasmacytoid DCs were compared to mDCs for cross-
presentation of HIV antigens derived from three different
apoptotic antigen donor cells: H9HIV cells, infected PHA
blasts, or 8E5 cells. 8E5 cells are CEM derivatives contain-
ing a defective proviral HIV genome that produces no
infectious virus. IFN-g production increased as a function
of the number of either pDC or mDCs in superimposable
curves, but not of apoptotic cells alone (Figure 6A). Activa-
tion of T cells was blocked with a MHC class I specific an-
tibody in a dose-dependent way (Figure 6B), showing that
T cells were activated through TCR and not by pDC-se-
creted cytokines. Moreover, specific inhibition by epoxo-
mycin underlines the necessity for intracellular processing
(Figure 6C). Therefore, human pDCs internalize apoptoticImdebris from cells expressing HIV antigens and crosspre-
sent them to specific CD8+ T cells.
DISCUSSION
Here we show that human pDCs internalize vaccinal lipo-
peptides, as well as apoptotic debris from cells express-
ing HIV antigens, and crosspresent viral antigens to HIV-
specific CD8+ T cells, in comparable efficiency to mDCs.
pDCs are susceptible to HIV infection (Lore et al., 2005;
Patterson et al., 2001), but experimental systems with un-
infected, transfected antigen donor cells excluded direct
presentation. Here pDCs took up apoptotic cell fragments
by phagocytosis. pDCs capture free HIV (Beignon et al.,
2005) and microvesicles from VSV-infected cells (Pichl-
mair et al., 2007). They may also take up apoptotic debris
in vivo in different diseases, like systemic lupus erythema-
tosus (Bave et al., 2003), through CD32 (Means et al.,
2005) or other pathogen recognition receptors (Blasius
and Colonna, 2006). Therefore, crosspresentation by
pDCs is likely to play a role in the pathogenesis of HIV
infection and of other diseases.
The mechanisms leading to crosspresentation in pDCs
is probably similar to those operating in mDCs (Chen et al.,
2004; Cresswell et al., 2005; Guermonprez et al., 2002;
Rock and Shen, 2005). In human and murine mDCs,
crosspresentation occurs after transport of the antigen
from the endosomes to the cytosol and digestion by the
proteasome (Guermonprez et al., 2002). Endosomal acid-
ification is regulated in immature mDCs (Trombetta et al.,
2003): the NADPH oxidase NOX2 maintains alkalinization
of early phagosomes, allowing crosspresentation of exog-
enous ovalbumin instead of degradation (Savina et al.,
2006). The lipopeptide used here as an antigenic model
for crosspresentation was previously shown to be endo-
cytosed by human mDCs, then digested by the protea-
some (Andrieu et al., 2003). In human pDCs, exit of the
lipopeptide into the cytosol is suggested by our data
showing the diffusion of Rhodamine outside of endosomal
compartments. This was reinforced by the requirement for
processing by the proteasome, which is localized outside
of the endosomes (Guermonprez et al., 2003). Our results
showing lower lipopeptide labeling in acidic than in non-
acidic vesicles suggest that most of the lipopeptide exits
to the cytosol before full lysosomal acidification, although
part of the lipopeptide may also undergo degradation
within acidic vesicles. The endosomal pathway used by
the lipopeptide intersected with that of CpG, which stimu-
lated crosspresentation in our experiments. Therefore,
crosspresentation of the lipopeptide in pDCs is dependent
on an endosome-to-cytosol pathway and may depend on
regulated acidification of the endosomal compartments,
similar to crosspresentation in mDCs (Savina et al., 2006).
We showed here that crosspresentation by pDCs re-
sulted in the activation of effector T cell responses such
as IFN-g secretion and cell proliferation. This activation
probably does not require type I IFN production, because
it was observed in unstimulated or IL-3-treated pDCs.
However, it was strongly stimulated by influenza virus.munity 27, 481–492, September 2007 ª2007 Elsevier Inc. 485
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Crosspresentation by Human Plasmacytoid DCFigure 3. Uptake and Processing Pathway of the LPPol Lipopeptide
(A) Left, FACS histogram showing purified pDCs incubated (red) or not (shaded) with 1 mM LPPol-Rho for 1 hr. Middle: confocal microscopy showing
the same pDCs, surface-labeled with anti-BDCA-2. Right: the percent of cells with LPPol+ vesicles increases with time at 37C and not at 4C.
(B) LP-Pol-Rho colocalizes with FITC-anti-BDCA-2-labeled vesicles after incubation at 37C for 30 min. Left: color merge; selected area is enlarged
in the middle. Middle: single channel intensity false-color labeling. Bottom middle: the mask shows maximal overlapping pixels (colocalization
coefficient > 0.8). Right: frequency of pDCs (n = 150) with colocalization increases with time.486 Immunity 27, 481–492, September 2007 ª2007 Elsevier Inc.
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Crosspresentation by Human Plasmacytoid DCFigure 4. pDCs Capture Apoptotic Infected T Cells and Crosspresent HIV Antigens
(A) PDCs were treated or not with different endocytosis inhibitors, washed, and incubated with PKH67-labeled apoptotic H9HIV cells at 4C or 37C.
Then, pDCs were washed and labeled with anti-HLA DR and anti-CD123 and analyzed by FACS. Results are represented as mean ± SEM of three
independent experiments.
(B and C) pDCs engulf apoptotic fragment from infected T cells. Plasmacytoid DCs were incubated with PKH26-labeled apoptotic H9-HIV cells and
analyzed by confocal microscopy after anti-BDCA2 and DAPI labeling.
(D) Plasmacytoid DCs present HIV antigens from apoptotic infected T cells to CD8+ T cell lines. H9HIV-loaded pDCs were stimulated with R-837 or
CpG, cultured with AZT, and used as APCs with Gag-, Nef-, or Pol-specific T cells in an IFN-g ELISPOT assay. As controls, H9HIV cells were added
without pDCs (no pDC).
(E) Plasmacytoid DCs present HIV antigens from apoptotic, infected PBMC. PHA blasts were infected or not with HIVLai, treated with SQ and AMD,
and incubated with pDCs in the presence of R-837. Then, loaded pDCs were incubated with CFSE-labeled PBMCs from an HIV+ patient, in the pres-
ence of SQ and AMD. After 6 days, CD3+ CD8+ T cell proliferation was analyzed by FACS. Alternatively, loaded pDCs were tested with Gag-specific
T cells in an ELISPOT assay as in (D). As a control, apoptotic HIV-infected PHA blasts were added without pDCs. All data are represented as
mean ± SEM (n = 3 replicates) and representative of at least three independent experiments.Presentation by pDCs often leads to other T cell re-
sponses, such as IL-10 secretion, and to tolerance (Tang
and Bluestone, 2006). This may explain why crosspresen-
tation by pDCs was not shown in other experimental set-
tings (Schnurr et al., 2005). Indeed, human pDCs can in-
duce CD4+ or CD8+ Treg cells in vitro after stimulationImwith CpG (Moseman et al., 2004), CD40L (Gilliet and Liu,
2002), or HSV-1 (Kawamura et al., 2006). In vivo, pDCs
also induce alloantigen-specific Treg cells (Ochando
et al., 2006). In addition, depletion of pDCs renders mice
susceptible to asthma in response to inhaled OVA, which
is presented by CD11c+ DCs (van Rijt et al., 2005). In this(C) LP-Pol-Rho colocalizes with DOTAP-CpG-FITC; pDCs were incubated first with the DOTAP-CpG-FITC (green) and washed, and then LPPol-Rho
(red) was added for 60 min at 37C. Afterwards, pDCs were washed and surface labeled at 4C with Cy5-anti-BDCA-2 (blue). Left: color merge;
selected area is enlarged in the middle. Middle: single channel intensity false-color labeling. Right: frequency of pDCs with colocalization.
(D) LPPol-Rho mostly does not colocalize with LysoTracker. Left: LPPol-Rho (red) and LysoTracker (green) were incubated at the same time, then
stained with Cy5-anti-BDCA-2 (blue). Selected areas are enlarged in the middle (color merge, single channel intensity false-color labeling and coloc-
alization mask). Right: frequency of pDCs with colocalization is low, starting only at 60 min. Data are represented as mean and representative of at
least two experiments.
Scale bars represent 10 mm.
(E and F) Proteasome processing is required for LPPol crosspresentation. PDCs were treated with proteasome inhibitors (E) lactacystin or (F) epox-
omycin 30 min before loading with LPPol as before and used in an IFN-g ELISPOT assay. NS, nonstimulated. Data are represented as mean ±
SEM (n = 3 replicates) and representative of at least four independent experiments.munity 27, 481–492, September 2007 ª2007 Elsevier Inc. 487
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Crosspresentation by Human Plasmacytoid DCFigure 5. Direct Antigen Presentation after pDC Infection Does Not Account for the TCell ResponsesObserved during HIV Antigen
Crosspresentation by pDCs
(A) Plasmacytoid DCs were loaded with apoptotic H9HIV cells in the presence of IL-3 and of different antiretroviral drugs. Then, pDCs were used as
APCs with HIV-1 Gag-specific CD8+ T cells in an IFN-g ELISPOT assay.
(B) Comparison between crosspresentation and direct presentation responses. pDCs were loaded for 12 hr with apoptotic primary PHAbHIV (that
contained HIV-1Lai as measured in Figure S3) in the presence of AZT and AMD (dot) or incubated with growing amounts of HIV-1Lai without inhibitors
(squares) and stimulated with CpG, then used as in (A).
(C) Crosspresentation of different HIV-1 protein-expressing cells by pDCs. Plasmacytoid DCs were loaded with apoptotic cells: either Jurkat or CEM
cells expressing Nef or murine fibroblasts transiently transfected with gag; they were then used as in (B). Data are represented as mean ± SEM (n = 3
replicates) and are representative of two independent experiments in (A) and (C) and three in (B).model, pDCs induce OVA-specific Treg cells (de Heer
et al., 2004). In HIV infection, pDCs crosspresenting HIV
antigens may thus participate in Treg cell induction, a
phenomenon suggested to play a role in pathogenesis
(Boasso et al., 2006).
Tolerance can be broken by IAV infection. Soluble, en-
dotoxin-free OVA is a weak stimulator for CD8+, CD4+ T
cell and antibody responses, but becomes strongly immu-
nogenic when IAV is administered 2–3 days prior to OVA
(Brimnes et al., 2003). Similarly, peptide-loaded pDCs
prime CD8+ T cells in vivo when they are stimulated by
IAV, and not by CpG (Schlecht et al., 2004). Intercurrent
IAV infection in mice sensitized intranasally to OVA either
breaks immunological tolerance when it is administered
simultaneously to OVA, or induces Th1-mediated protec-
tion when it is administered later (van Rijt et al., 2005). It
will be of great interest to determine whether this is due
to crosspriming by pDCs.
In summary, crosspresentation by pDCs has strong
potential implications in physiology or pathogenesis. First,
it may induce tolerance most of the time, but intercurring
infection or other stimulations may break this tolerance
and yield unwanted allergic or autoimmune responses.
Second, the ability of pDCs to crosspresent antigens
should be taken into account for vaccination or immune
therapies, in order to trigger and stimulate the desired
subsets of DCs, to induce either tolerance or full effector
responses.
EXPERIMENTAL PROCEDURES
Peptides, Lipopeptides, Antibodies, and Virus
HIV-1Lai HLA-A2-restricted peptides Pol476-484 (ILKEPVHGV), Tax11–19
(LLFGYPVYV), and Gag77-85 (SLYNTVATL) and HLA-A3-restricted
Nef73-82 (QVPLRMTYK) were from Neosystem (Strasbourg, France).
LPPol (NH2-K(N3-Pam)PLTEEAELELAENREILKEPVHGV-COOH in-
cluding Pol461-484), LPPol-Rho (substitution of His482 by N3-rhodamine-
Lys), LPNef (NH2-GVFPVTPQVPLRPMTYKAAVDLSHFLKEKGGL(N3-
Pam)-COOH, including Nef66-97) (Andrieu et al., 2003), and the vaccinal488 Immunity 27, 481–492, September 2007 ª2007 Elsevier Inclipopeptide preparation LPHIV1, from ANRS, were used at 1mM of each




Monoclonal Abs directed against the following molecules were
used: CD11c (pure, PE or APC), lineage-FITC, HLA DR-PerCP, CD3-
APCCy7 (Becton Dickinson, BD), CD8-PerCP (Caltag), CD123-APC,
BDCA-2 (pure, PE; Miltenyi Biotech), HLA-A2 (BB7.2), HLA-A3
(GAPA3), and MHC class I (W6/32, kind gifts from F. Connan). Goat
anti-mouse Ig (GaMIg)-FITC and GaMIg-Cy5 were from Caltag.
A mouse-adapted strain of influenza A/Puerto Rico/8/34 virus (PR8)
was grown in 10-day-old embryonated hen eggs. Allantoic fluid was
harvested on day 2 and clarified by centrifugation at 1500 3 g for
15 min. Aliquots were stored at 80C. Titers were determined by
standard plaque assay in the presence of 2 mg/ml TPCK-treated tryp-
sin with Madin-Darby canine kidney cells.
Cell Purification, Culture, Transfection, and HLA Typing
HLA-typed buffy coats or cytapheresis residues were obtained from
healthy donors within a convention with INSERM from French Blood
Bank (EFS-Alsace) or from Transfusion Medicine Unit, Cochin Hospi-
tal, with informed consent from all subjects and according to ethical
guidelines. PBMCs separated by Ficoll-Paque (Pharmacia) were first
depleted of B cells by CD19+ MACS microbeads. mDCs were selected
from the CD19 fraction with BDCA-1 microbeads (Miltenyi). The
mDC fraction was then further depleted for non-DCs with the DC-
negative selection kit (Dynal), and finally pDCs were isolated by
BDCA-4-positive selection kit (Miltenyi Biotech). In some cases,
pDCs were selected from the lineage, mDC fraction by Diamond
pDC isolation kit (Miltenyi). PDCs were routinely 94%–99.2% pure
with a median of 96.5% and mDCs were 94% pure, as assessed by
FACS Canto analysis (BD). Myeloid DCs and pDCs were maintained
in complete medium (CM: RPMI 1640-glutamax containing 100 U/ml
penicillin; 100 mg/ml streptomycin, 1% nonessential amino acids,
1 mM sodium pyruvate, 10 mM HEPES buffer, Life Technologies) +
10% heat inactivated autologous plasma. They were cultured in poly-
propylene tubes at 2.53 105/ml with either IL-3 (R&D Systems, 10 ng/
ml), LPS (Sigma, 500 ng/ml), CpG A phosphorothioate (2216, 3 mM,
Invitrogen), imiquimod (Invivogen, Toulouse, France, R-837, 10 mM),
or IAV (1 PFU/cell).
HIV-specific CD8+ primary T cell lines were generated with PBMCs
from HLA-A2 or A3 HIV+ individuals from cohort studies with the
approval of Cochin Hospital’s ethics committee. They were cultured.
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Crosspresentation by Human Plasmacytoid DCFigure 6. HIV Antigen Processing by pDCs
(A) mDCs and pDCs induce equivalent responses to T cell lines. Growing amounts of pDCs or mDCs were incubated with apoptotic H9HIV (left), HIV-
PHA blasts (middle), or 8E5 cells (right) in the presence of CpG or LPS, respectively, and of SQ and AMD, and used as APCs with HIV-1 Gag-specific
CD8+ T cells in an IFN-g ELISPOT assay. Alternatively, apoptotic cells were used without DCs in dose-response curves.
(B) Loaded pDCs were incubated with increasing concentrations of anti-MHC class I and used as APCs as in (A).
(C) pDCs were treated with epoxomycin before loading with apoptotic cells and used as APCs as in (A). Data are represented as mean ± SEM (n = 3
replicates) and are representative of two independent experiments in (B) and three in (A) and (C).in CM + 5% human serum (Biowest, Nouaille´, France), stimulated with
1 mM Pol476-484, Gag77-85 (HLA-A2-restricted), or Nef73-82 (HLA-A3-re-
stricted) peptide, and maintained for 2–3 weeks at 0.7 3 106–1 3
106 cells /ml, adding IL-2 (10 U/ml, Roche) twice a week.
Uninfected or chronically infected H9 cells were cultured as before
(Maran˜o´n et al., 2004). PHA blasts were prepared as follows: PBMCs
isolated from a healthy donor (HLA A2 A3) were cultured at 0.5 3
106/ml with PHA (Sigma, 1 mg/ml) and 10 U/ml IL-2 for 2 days, then
infected or not with 100 ng/ml p24 equivalent concentration of HIVLai
for 12 hr.
8E5 cells are derived from CEM cells and contain a defective proviral
HIV genome that produces no infectious virus. CEM clones stably
expressing the HIV-1Lai nef gene were generated by transduction of
CEM cells with a murine retroviral vector (Schwartz et al., 1993). Jurkat
cells expressing HIV-1 nef were obtained by transient transduction
with a lentiviral vector as described (Sol-Foulon et al., 2004).
L cells were transfected via Fugen (Roche Diagnostics) with a plas-
mid prepared as follows. An HIV gag cDNA clone from the Lai isolate
(accession #K02013) was digested with EcoRI and MunI and cloned
in the EcoRI restriction site of pEGFP-N3 (Clontech, Mountain View,
CA), so that the first 374 amino acids of Gag were expressed as a
protein fused to eGFP.ImHLA typing of different cells was performed by molecular biology
methods in the HLA-typing facility of the Blood bank, EFS-Alsace,
Strasbourg: H9 (HLA-A*01; B*15 -B*1501 most probable, equivalent
to B62 serological typing), CEM and 8E5 (HLA-A*01, *31; B*08, *40
-*4001 most probable, equivalent to B60 serological typing), Jurkat
(HLA-A*03; B*07, *35). HLA-A2 or -A3 expression was tested on
PBMCs from healthy donors by mAb labeling and FACS.
Lipopeptide or Apoptotic Fragment Uptake
To follow lipopeptide acquisition by pDCs or mDCs, PBMCs were
incubated with different concentration of LPPol-Rho in CM (37C,
30 min). Cells were then extensively washed at 4C in PBS, 5%
autologous plasma, and 2 mM EDTA and surface labeled with anti-
Lineage-FITC, anti-HLA DR-PerCP, and either anti-CD11c-APC or
anti-CD123-APC, before analyzis by FACS. To study apoptotic frag-
ment engulfment, H9 or H9HIV cells were labeled with PKH26 or 67 ac-
cording to manufacturer instructions (Sigma), extensively washed, and
UV-irradiated at 312 nm for 30 min. After 24 hr, apoptotic cells were
treated with bicyclam AMD3100 (AMD, Sigma, 5 mg/ml) and incubated
for 8 hr at 37C at a ratio of 1:1 with pDCs preincubated for 30 min or
not with LatB (1 mM), CCD (10 mM), or Dimethylamiloride (DMA, 50 mM;
all from Calbiochem). Apoptotic cell fragment capture by pDCs wasmunity 27, 481–492, September 2007 ª2007 Elsevier Inc. 489
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Crosspresentation by Human Plasmacytoid DCanalyzed by FACS according to size/granularity criteria and HLA DR
and CD123 expression or by confocal microscopy.
Confocal Microscopy
Purified pDCs were incubated with 1 mM LPPol-Rho in CM at 37C,
extensively washed in PBS, 5% autologous plasma, and 2 mM
EDTA and labeled with anti-BDCA-2 mAbs (30 min, 4C), washed,
and labeled with GaMIg-FITC (30 min, 4C). To analyze the LPPol
endosomal pathway in pDC, cells were first labeled with anti-BDCA-
2 as described before, then incubated with 1 mM LPPol-Rho for differ-
ent times at 37C. Endosomal compartments were also labeled
(30 min, 37C) with FITC-CpG B (Invivogen, 1 mM) complexed with
1,2 dioleoyloxy-3-trimethylammonium-propane (DOTAP, Roche Diag-
nostic) (Honda et al., 2005), then cells were extensively washed and
incubated with 1 mM LPPol-Rho at 37C. Acidic organelles were visu-
alized with 100 nM LysoTracker green DND 26 (Molecular Probes)
during LPPol-Rho incubation. Cells were washed in PBS, fixed in 4%
paraformaldehyde, and mounted (Fluorescent Mounting Medium,
Dako Cytomation). Fluorescent images were acquired on an inverted
Leica LSM TSC SP2 AOBS confocal microscope (633 oil-immersion
objective, 1.4 NA plan apochromat). Multiple color images were
acquired by scanning in sequential mode to avoid crossexcitation.
Images were analyzed with ImageJ 1.37c and colocalization finder
from ImageJ. Colocalization frequencies were quantified by counting
cells (n = 150) respecting mask criteria (Pearson coefficient = 0.8),
with a minimal threshold of fluorescence intensity for both fluoro-
chromes and a ratio of 80%.
Crosspresentation
Antigen donor cells were washed, UV-irradiated (312 nm) for 20 min
(45 min for fibroblasts), and incubated at 2 3 106 cells/ml in CM +
10% heat inactivated plasma for 8 hr. Maturation stimuli, AZT (Sigma;
200 nM), Saquinavir (SQ, Roche, 1 mM), or AMD were added as indi-
cated. 50,000 pDCs or mDCs were cultured with 1 mM lipopeptide or
with apoptotic cells at a ratio of 1:1 in CM + 10% heat inactivated au-
tologous plasma for 12 hr. After loading, DCs were extensively washed
and used (7,000–15,000/well) in a 12–16 hr IFN-g ELISPOT assay (Fon-
teneau et al., 2003) with T cell lines as effectors (21,000–45,000/well).
DCs from HLA-A2+ donors were used in most experiments, but DCs
from HLA-A3+ donors were used when HLA-A3-restricted, Nef73-82-
specific T cell responses were tested. HLA typing of DCs and antigen
donor cells and HLA restriction of the observed response are shown for
each experiment in Table S1. In some experiments, CD4+ T cells and
CD8+ T cells were depleted or enriched with anti-CD4 or -CD8 mAb-
coated magnetic beads (Miltenyi). To inhibit proteasome activity,
pDCs were treated 30 min before lipopeptide or apoptotic cell loading
and during the whole period of antigen loading with epoxomycin
(Alexis) or lactacystin (Calbiochem). All conditions were tested in
triplicate.
CD8+ T Lymphocyte Proliferation
HIV-1Lai-infected or uninfected PHA blasts from a non-HLA-A2 healthy
donor were washed and cultured for 24 hr in the presence of SQ and
UV irradiated. HLA-A2+ pDCs were loaded with apoptotic cells at a
ratio of 1:1 in the presence of R-837, SQ, and AMD for 24 hr. They
were then cultured in SQ and AMD with primary CFSE-labeled PBMCs
(1 mM; Molecular Probes) from an HLA-A2+ HIV+ patient, at a
pDC:PBMC ratio of 1:5. Residual APCs were removed from PBMCs
by adhesion. 5 to 10 U/ml of IL2 (Roche) was added at days 1 and 3
to substitute for the lack of helper cells. After 6 days, cells were labeled
for CD3 and CD8 and analyzed by FACS.
Direct Presentation
Viral amounts contained in apoptotic cells were evaluated by p24
ELISA (Innotest HIV Antigen mAb kit, Innogenetics). Different amounts
of free virus were incubated with pDCs in an ELISPOT assay. 5 3 104
pDCs were incubated with H9 or H9HIV or equivalent amount of free
HIV-1Lai virus and stimulated or not with IAV for 12 hr. Supernatants490 Immunity 27, 481–492, September 2007 ª2007 Elsevier Inc.were collected after 48 or 72 hr and incubated with 105 CEM cells to
amplify infectious virus. After 20 days, the virus contained in the super-
natant was evaluated by p24 ELISA.
Supplemental Data
Three figures and one table are available at http://www.immunity.com/
cgi/content/full/27/3/481/DC1/.
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